Protalix BioTherapeutics Inc. (AMEX:PLX) saw an upside of 1.24% to $1.68 after adding $0.02 on Monday. The 5-day average trading volume is 1,198,734 shares of the company’s common stock. It has gained $1.9300 in the past week and touched a new high 4 times within the past 5 days. An average of 846,938 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,143,999.
PLX’s 1-month performance is -6.63% or -$0.1400 on its low of $1.4250 reached on 07/26/23. The company’s shares have touched a 52-week low of $1.00 and high of $3.55, with the stock’s rally to the 52-week high happening on 05/05/23. YTD, PLX has achieved 22.67% or $0.2900 and has reached a new high 25 times. However, the current price is down -52.66% from the 52-week high price.
Valuation Metrics
PLX stock has a beta of 1.34. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.03 while the price-to-book (PB) in the most recent quarter is 84.03.
Protalix BioTherapeutics Inc.’s quick ratio for the period ended December 30 was 1.10, with the current ratio over the same period at 1.80. In terms of profitability, the gross margin trailing 12 months is 59.50%. The trailing 12-month EBITDA margin is -25.04% while for the period ending December 30, Protalix BioTherapeutics Inc.’s operating margin was -32.90%. The firm’s gross profit as reported stood at $28.05 million against revenue of $47.64 million.
Earnings Surprise
For the quarterly period ending December 30 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 26.84% to -$3.13 million, while revenue of -$3.74 million was -19.49% off the previous quarter. Analysts expected PLX to announce -$0.15 per share in earnings in its latest quarter, but it posted -$0.07, representing a 53.30% surprise. EBITDA for the quarter stood at more than -$2.1 million. PLX stock balance sheet for the quarter ending December 30 shows that total liabilities totaled 65.55 million, with total debt at $33.57 million. Shareholders hold equity totaling $65.42 million.
Let’s look briefly at Protalix BioTherapeutics Inc. (PLX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 04 August was 43.75% to suggest the stock is trending Neutral, with historical volatility in this time period at 52.19%.
The stock’s 5-day moving average is $1.6700, reflecting a +3.75% or $0.0600 change from its current price. PLX is currently trading -10.75% above its 20-day SMA, -16.58% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -27.19% and SMA200 by+59.62%.
Stochastic %K and %D was 60.24% and 62.77% and the average true range (ATR) pointed at 0.1191. The RSI (14) points at 40.71%, while the 14-day stochastic is at 46.53% with the period’s ATR at 0.1149. The stock’s 9-day MACD Oscillator is pointing at 0.0267 and 0.0264 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Protalix BioTherapeutics Inc. (AMEX: PLX), H.C. Wainwright reiterated its a Buy rating for the company but lifted their price target by $3 to $11. Analysts offering their rating for PLX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate PLX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is PLX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $16.00 and a high of $16.00, with their median price target at $16.00. Looking at these predictions, the average price target given by analysts is for Protalix BioTherapeutics Inc. (PLX) stock is $16.00.
